Boisse N R, Okamoto M
J Pharmacol Exp Ther. 1978 Mar;204(3):514-25.
After "chronically equivalent" barbital and pentobarbital dosing for 5 weeks, treatments were abruptly stopped and the animals were carefully observed for signs of barbiturate withdrawal. The severity of withdrawal was assessed at preset times by counting the number of grand mal type convulsions and subjectively rating 20 additional motor, autonomic and behavioral signs including tremors, twitches, myoclonic jerks, postural disturbances and motor incoordination. Ratings achieved at peak intensity (raw scores) and their incidences were used to compute "total intensity scores" for each graded sign. For all quantitative measures, withdrawal signs were less severe for barbital than for pentobarbital, with strikingly lower (P less than .05) incidences of convulsions (6.3% vs. 100%), bizarre (hallucinatory) behavior (6.3% vs. 41.3), and death (0% vs. 100%). The withdrawal signs for barbital appeared later, developed more slowly and persisted longer than those for pentobarbital. That the onset and then peak of withdrawal signs occurred when the extents of decline from peak blood concentration of barbital and pentobarbital were similiar suggests that the time course of withdrawal might be inversely related to residual concentrations of drug, i.e., negative dose-response.
在给予相当于慢性剂量的巴比妥和戊巴比妥5周后,突然停止给药,并仔细观察动物有无巴比妥戒断症状。在预设时间通过计数癫痫大发作类型的惊厥次数以及主观评定另外20种运动、自主神经和行为症状(包括震颤、抽搐、肌阵挛性抽搐、姿势障碍和运动不协调)来评估戒断的严重程度。将达到峰值强度时的评分(原始分数)及其发生率用于计算每个分级症状的“总强度分数”。对于所有定量测量,巴比妥引起的戒断症状比戊巴比妥轻,惊厥发生率(6.3%对100%)、怪异(幻觉)行为发生率(6.3%对41.3%)和死亡率(0%对100%)显著更低(P<0.05)。巴比妥引起的戒断症状出现较晚,发展较慢且持续时间比戊巴比妥长。当巴比妥和戊巴比妥血药浓度从峰值下降的程度相似时出现戒断症状的起始和峰值,这表明戒断的时间过程可能与药物的残留浓度呈负相关,即负剂量反应。